A multicenter, open-label study of Nipent [pentostatin], Cytoxan [cyclophosphamide] and Rituxan [rituximab] in patients with previously untreated or treated chronic lymphocytic leukaemia.
Phase of Trial: Phase IV
Latest Information Update: 27 Feb 2017
At a glance
- Drugs Cyclophosphamide (Primary) ; Pentostatin (Primary) ; Rituximab (Primary)
- Indications Chronic lymphocytic leukaemia
- Focus Therapeutic Use
- 08 Dec 2005 Additional lead trial centres and investigators identified as reported by ClinicalTrials.gov.
- 22 Oct 2005 New trial record.